Clinical study of SM-11355 in patients with hepatocellular carcinoma (Phase III Study)
Phase 3
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-jRCT2080220609
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients histologically and/or clinically diagnosed with hepatocellular carcinoma, with a measurable lesion, patients with tumor stain in contrast enhanced CT imaging, patients for whom hepatectomy, PEIT, PMCT, or RFA is not indicated
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy: Overall survival
- Secondary Outcome Measures
Name Time Method